PubRank

Jedd D Wolchok

Author PubWeight™ 344.88‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010 67.34
2 Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011 26.90
3 Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013 18.08
4 Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015 14.71
5 Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 2012 11.14
6 Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012 8.46
7 Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015 7.51
8 Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 2011 6.44
9 Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012 5.32
10 Antibody therapy of cancer. Nat Rev Cancer 2012 5.17
11 Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 2004 4.06
12 Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 2013 3.83
13 CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A 2008 3.80
14 KIT as a therapeutic target in metastatic melanoma. JAMA 2011 3.49
15 Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 2012 3.37
16 Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 2011 3.12
17 Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 2010 3.03
18 Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A 2011 2.90
19 Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res 2010 2.73
20 Defining the critical hurdles in cancer immunotherapy. J Transl Med 2011 2.32
21 The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys 2012 2.29
22 Immune modulation in cancer with antibodies. Annu Rev Med 2013 2.23
23 Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res 2011 2.20
24 Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med 2012 2.19
25 Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling. J Clin Oncol 2003 2.18
26 Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med 2013 2.13
27 Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol 2010 1.98
28 Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res 2008 1.94
29 At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol 2013 1.90
30 Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation. Blood 2012 1.81
31 A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J Immunol 2003 1.81
32 Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015 1.80
33 Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. Blood 2010 1.77
34 The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. Cancer Immun 2008 1.75
35 Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS One 2010 1.69
36 Stage-IV melanoma and pulmonary metastases: factors predictive of survival. Ann Surg Oncol 2007 1.63
37 OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J Exp Med 2009 1.63
38 Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. J Clin Invest 2006 1.59
39 Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer Res 2006 1.57
40 Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin Cancer Res 2013 1.51
41 Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. J Exp Med 2009 1.47
42 Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy. J Clin Oncol 2014 1.47
43 Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 2003 1.43
44 Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood 2010 1.41
45 Melanoma vaccines. Cancer Invest 2002 1.37
46 Therapeutic implications of the emerging molecular biology of uveal melanoma. Clin Cancer Res 2011 1.34
47 Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma. Clin Cancer Res 2013 1.34
48 Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clin Cancer Res 2013 1.33
49 Cutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right. J Immunol 2009 1.32
50 Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype. J Exp Med 2012 1.32
51 Monoclonal antibodies in cancer therapy. Cancer Immun 2012 1.31
52 Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med 2014 1.29
53 Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res 2013 1.29
54 Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked database. Appl Health Econ Health Policy 2009 1.27
55 CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine 2004 1.25
56 Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: how different are these from conventional treatment responses? Am J Clin Oncol 2012 1.24
57 Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer 2013 1.22
58 Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma. Mol Ther 2008 1.22
59 Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses. Cytotherapy 2009 1.21
60 Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo. Adv Immunol 2006 1.21
61 Phase II study of extended-dose temozolomide in patients with melanoma. J Clin Oncol 2008 1.19
62 Modulation of GITR for cancer immunotherapy. Curr Opin Immunol 2012 1.17
63 Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. Am J Vet Res 2011 1.17
64 Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. Cancer Immun 2013 1.17
65 Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity. Oncogene 2003 1.16
66 Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancer Immunol Res 2013 1.16
67 Multiple pathways to tumor immunity and concomitant autoimmunity. Immunol Rev 2002 1.14
68 Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles. Clin Cancer Res 2005 1.14
69 Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer 2005 1.13
70 Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. Invest New Drugs 2012 1.12
71 Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin Cancer Res 2003 1.12
72 CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases. Cancer Immunol Immunother 2011 1.10
73 Combining cancer immunotherapy and targeted therapy. Curr Opin Immunol 2013 1.09
74 Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. Cancer Immun 2009 1.09
75 Ipilimumab for patients with advanced mucosal melanoma. Oncologist 2013 1.09
76 Surgical management of melanoma of the gallbladder: a report of 13 cases and review of the literature. Am J Surg 2007 1.08
77 Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination. Int J Cancer 2005 1.07
78 Immunity to cancer through immune recognition of altered self: studies with melanoma. Adv Cancer Res 2003 1.07
79 Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 2014 1.05
80 Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains. Clin Cancer Res 2006 1.04
81 Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immun 2006 1.04
82 Immunomodulatory therapy for melanoma: ipilimumab and beyond. Clin Dermatol 2013 1.04
83 Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol 2003 1.03
84 Rapid eradication of a bulky melanoma mass with one dose of immunotherapy. N Engl J Med 2015 1.03
85 Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity. PLoS One 2010 0.99
86 The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol 2016 0.99
87 Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. Cancer J 2012 0.97
88 Identification of cancer-testis genes expressed by melanoma and soft tissue sarcoma using bioinformatics. Cancer Immun 2005 0.97
89 Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy. Am J Clin Oncol 2015 0.97
90 Treatment of locally recurrent mucosal melanoma with topical imiquimod. J Clin Oncol 2011 0.97
91 Checkpoint modulation in melanoma: an update on ipilimumab and future directions. Curr Oncol Rep 2013 0.94
92 Genetic basis for clinical response to CTLA-4 blockade. N Engl J Med 2015 0.94
93 Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo. Clin Cancer Res 2011 0.92
94 Radiotherapy after surgical resection for head and neck mucosal melanoma. Am J Clin Oncol 2010 0.92
95 Altered development of NKT cells, γδ T cells, CD8 T cells and NK cells in a PLZF deficient patient. PLoS One 2011 0.92
96 Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma. Cancer 2006 0.91
97 Immunological insights from patients undergoing surgery on ipilimumab for metastatic melanoma. Ann Surg Oncol 2013 0.91
98 Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine. Clin Cancer Res 2007 0.91
99 Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy. Cancer Immun 2010 0.91
100 Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection. Clin Cancer Res 2010 0.90
101 Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers. Immunotherapy 2010 0.90
102 Detection of intra-tumor self antigen recognition during melanoma tumor progression in mice using advanced multimode confocal/two photon microscope. PLoS One 2011 0.88
103 DNA vaccines against cancer. Hematol Oncol Clin North Am 2006 0.88
104 Frequent MAGE mutations in human melanoma. PLoS One 2010 0.87
105 Anti-GITR antibodies--potential clinical applications for tumor immunotherapy. Curr Opin Investig Drugs 2010 0.87
106 The role of the immune system in early epithelial carcinogenesis: B-ware the double-edged sword. Cancer Cell 2005 0.87
107 GM-CSF DNA induces specific patterns of cytokines and chemokines in the skin: implications for DNA vaccines. Cytokines Cell Mol Ther 2002 0.87
108 Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses after murine allogeneic bone marrow transplantation. Blood 2008 0.87
109 Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy. Cancer J 2011 0.86
110 Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines. J Transl Med 2004 0.86
111 Is tumor immunity the same thing as autoimmunity? Implications for cancer immunotherapy. J Clin Oncol 2006 0.86
112 Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma. Cancer Res 2008 0.86
113 Immunological validation of the EpitOptimizer program for streamlined design of heteroclitic epitopes. Vaccine 2007 0.85
114 Mechanisms of immunization against cancer using chimeric antigens. Mol Ther 2008 0.85
115 Immunotherapy: The path to win the war on cancer? Cell 2015 0.84
116 Immune rejection of mouse tumors expressing mutated self. Cancer Res 2009 0.84
117 The antitumor immunity of ipilimumab: (T-cell) memories to last a lifetime? Clin Cancer Res 2012 0.84
118 Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J Clin Oncol 2002 0.83
119 Combination of epitope-optimized DNA vaccination and passive infusion of monoclonal antibody against HER2/neu leads to breast tumor regression in mice. Vaccine 2011 0.83
120 Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice. Blood 2014 0.82
121 Immunotherapy of Melanoma. Prog Tumor Res 2015 0.82
122 Two Distinct Categories of Focal Deletions in Cancer Genomes. PLoS One 2013 0.82
123 Ipilimumab and whole brain radiation therapy for melanoma brain metastases. J Neurooncol 2014 0.82
124 Markers for anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy in melanoma. Methods Mol Biol 2014 0.81
125 Hiding the road signs that lead to tumor immunity. J Exp Med 2011 0.80
126 CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma. Clin Cancer Res 2005 0.80
127 Modulation of CTLA-4 and GITR for cancer immunotherapy. Curr Top Microbiol Immunol 2011 0.80
128 Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates. Cancer Immunol Res 2014 0.80
129 Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell 2016 0.80
130 DNA immunization against tissue-restricted antigens enhances tumor immunity after allogeneic hemopoietic stem cell transplantation. J Immunol 2006 0.80
131 Induction of autoantibodies against tyrosinase-related proteins following DNA vaccination: unexpected reactivity to a protein paralogue. Cancer Immun 2002 0.79
132 Meeting report: fourth international congress of the Society for Melanoma Research. Pigment Cell Melanoma Res 2008 0.79
133 CD4 help and tumor immunity: beyond the activation of cytotoxic T lymphocytes. Ann Surg Oncol 2004 0.79
134 Myeloid-derived suppressor sells and the efficacy of CD8(+) T-cell immunotherapy. Oncoimmunology 2013 0.79
135 How can we tell when cancer vaccines vaccinate? J Clin Oncol 2003 0.79
136 Selecting antigens for cancer vaccines. Nat Biotechnol 2012 0.78
137 Strategies to overcome immune ignorance and tolerance. Semin Cancer Biol 2002 0.78
138 CTLA-4 antibodies: new directions, new combinations. Oncology (Williston Park) 2014 0.78
139 Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res 2015 0.77
140 Development of effective vaccines for old mice in a tumor model. Vaccine 2008 0.77
141 Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. N Engl J Med 2015 0.77
142 The role of lipopolysaccharide in T-cell responses following DNA vaccination. Vaccine 2003 0.77
143 Antigens recognized by autologous antibodies of patients with soft tissue sarcoma. Cancer Immun 2005 0.76
144 Improving the therapeutic benefits of ipilimumab. Oncology (Williston Park) 2010 0.75
145 Cancer's off switch. Sci Am 2014 0.75
146 DNA vaccines for melanoma. Cancer Chemother Biol Response Modif 2005 0.75
147 Keratoacanthomas associated with imatinib mesylate. Acta Oncol 2010 0.75
148 Corrigendum: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 2016 0.75
149 Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma. Melanoma Res 2016 0.75
150 Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell 2017 0.75
151 Completely regressed cutaneous melanocytic lesion: was it benign or was it malignant? Semin Oncol 2009 0.75